Drug-eluting stent implantation in ST-elevation acute myocardial infarction: 'real world' 30-day and mid-term results

Cardiovasc Revasc Med. 2007 Jan-Mar;8(1):5-8. doi: 10.1016/j.carrev.2006.08.002.

Abstract

Primary percutaneous coronary intervention (PCI) with stent implantation is the preferred method of reperfusion for ST-elevation acute myocardial infarction. Concern remains over the use of drug-eluting stents in the acute ST-elevation myocardial infarction setting, with limited published reports on their use for this application. We studied 64 consecutive patients presenting with an acute ST-elevation myocardial infarction who underwent mechanical reperfusion with implantation of a drug-eluting stent. Both sirolimus- and paclitaxel-eluting stents were used. Primary outcome was the occurrence of major adverse cardiac events, defined as death, nonfatal reinfarction or clinically driven target vessel revascularization. Post-procedural success was achieved in 63 patients (98%). In-hospital mortality was 1.6%. During a median follow-up of 234 days, there were no cases of stent thrombosis, reinfarction or reintervention. These findings conducted in a 'real world' practice setting in the United States demonstrate that drug-eluting stent implantation for acute ST-elevation myocardial infarction is safe and effective, with a low rate of major adverse cardiac events during mid-term follow-up.

MeSH terms

  • Acute Disease
  • Aged
  • Aged, 80 and over
  • Angioplasty, Balloon, Coronary*
  • Antineoplastic Agents, Phytogenic / administration & dosage
  • Drug Delivery Systems*
  • Drug Implants*
  • Electrocardiography
  • Female
  • Follow-Up Studies
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Male
  • Middle Aged
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / surgery
  • Myocardial Infarction / therapy*
  • Paclitaxel / administration & dosage
  • Sirolimus / administration & dosage
  • Stents*
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Phytogenic
  • Drug Implants
  • Immunosuppressive Agents
  • Paclitaxel
  • Sirolimus